ZVRA
Zevra Therapeutics Inc.
11.00$
-2.0%
vs. previous close
Closing price · As of: Sep 25, 2026
Statements
Balance Sheet
All figures as a percentage of total assets in the same period.
Tick rows to compare them in a chart (up to 4)
| Line item | 2014 | 2015 | 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 100.0% | 100.0% | 100.0% | 100.0% | 100.0% | 100.0% | 100.0% | 100.0% | 100.0% | 100.0% | 100.0% | 100.0% | |
| 74.9% | 97.0% | 87.6% | 87.5% | 88.7% | 66.4% | 74.8% | 86.5% | 80.5% | 50.4% | 48.3% | 78.3% | |
| 74.8% | 58.0% | 19.7% | 20.7% | 68.8% | 30.6% | 37.6% | 84.5% | 56.8% | 25.0% | 19.0% | 21.9% | |
| 74.8% | 92.1% | 79.8% | 80.5% | 81.0% | 30.6% | 37.6% | 84.5% | 71.8% | 39.3% | 39.0% | 67.1% | |
| 0.2% | 4.3% | 6.0% | 4.0% | 0.5% | 17.8% | 23.0% | 1.1% | 7.2% | 10.1% | 5.9% | 8.2% | |
| – | -4.3% | 1.3% | 0.0% | 0.8% | – | 1.0% | 0.0% | – | 14.0% | 1.1% | 0.6% | |
| – | – | – | – | – | 28.6% | 21.3% | 1.5% | 1.5% | – | – | – | |
| – | – | – | – | – | – | – | – | 0.0% | 2.7% | 2.6% | 1.7% | |
| – | – | – | – | – | – | – | – | – | 40.2% | 38.7% | 2.3% | |
| 277.2% | 118.2% | 122.0% | 209.6% | 348.9% | 808.6% | 692.5% | 4.4% | 34.9% | 64.1% | 77.7% | 45.7% | |
| 28.7% | 15.0% | 7.8% | 21.9% | 44.9% | 51.7% | 67.2% | 3.2% | 10.4% | 42.8% | 19.1% | 13.8% | |
| 6.1% | 6.2% | 0.2% | 6.7% | 13.3% | 2.7% | 7.9% | 0.3% | 4.5% | 22.2% | 0.2% | 0.1% | |
| 11.5% | 2.2% | 0.6% | 4.2% | 13.9% | 10.8% | 10.5% | 0.4% | 3.1% | 8.1% | 7.3% | 0.9% | |
| – | – | – | – | – | 736.1% | 607.1% | – | 11.1% | 2.9% | 33.4% | 21.7% | |
| -177.2% | -18.2% | -22.0% | -109.6% | -248.9% | -708.6% | -592.5% | 95.6% | 65.1% | 35.9% | 22.3% | 54.3% | |
| -365.8% | -188.1% | -142.9% | -314.0% | -827.0% | -2,338.6% | -2,306.0% | -200.9% | -306.7% | -232.0% | -283.7% | -148.2% | |
| 5.6% | 0.8% | 1.1% | 1.7% | 4.2% | 17.6% | 35.5% | 22.4% | 29.9% | 20.6% | 26.0% | 20.1% |
Data as of: September 25, 2026 · Source: fundamental data & SEC filings (annual and quarterly reports, 10-K/10-Q)
Note: pure fact-based analysis, not investment advice and not a solicitation to buy or sell. All figures without guarantee.